Multiple sclerosis
MS is an autoimmune demyelinating disease that, in the majority of patients, evolves into a chronic neurodegenerative disease retaining an inflammatory component. As such, MS sits at the interface of immunology, inflammation and neuroscience. No single disease model adequately provides all the clinical features of MS.
The world-leading expertise that Aquila has in MS research allows us to provide a unique service to understand efficacy and mode-of-action across the MS disease interface. The MBP-Tracker model allows us to specifically follow the physical and functional fate of the T cells that initiate the autoimmune inflammatory lesion.
To complement this we have designed predictive moderate-throughput in vitro assays to provide best-evidence, target-based decisions at the lead compound selection point. Similarly, our moderate throughput in vitro remyelination models allow screening for the best candidates for further testing.
Contact us for more information